Summary & Overview
CPT 78122: Whole Blood Volume Study via Isotope Dilution
CPT code 78122 represents a diagnostic nuclear medicine procedure to determine whole blood volume, including red blood cell and plasma volumes, using an isotope dilution technique with radiolabeled autologous red blood cells. This test is used to quantify circulating blood components for clinical decisions in hematology, transfusion planning, and complex volume-status assessments. Nationally, accurate coding of this procedure matters for consistent clinical reporting, appropriate facility billing, and resource allocation in imaging and nuclear medicine services.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for why the study is ordered, typical sites of service where it is performed, and common modifiers and administrative elements associated with billing. The publication outlines benchmarks and coverage considerations where available, highlights coding nuances for documentation and reporting, and summarizes policy and reimbursement updates affecting nuclear medicine diagnostic studies. The content is designed to inform coding professionals, billing managers, and clinical leaders on national coding practice and operational implications for CPT code 78122.
Billing Code Overview
CPT code 78122 describes a whole blood volume study using an isotope dilution technique. The procedure measures total blood volume, including red blood cell volume and plasma volume, by injecting a radiopharmaceutical or radiotracer and the patient’s own red blood cells tagged with a tracer, then calculating volumes after adequate mixing.
-
Service type: Diagnostic nuclear medicine / radiolabeled blood volume study
-
Typical site of service: Hospital outpatient imaging department, nuclear medicine facility, or specialized diagnostic center
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with congestive heart failure and unexplained anemia is referred for measurement of whole blood volume to differentiate true anemia from plasma volume expansion. The nuclear medicine team schedules a quantitative blood volume study using isotope dilution. The procedure involves withdrawing a baseline blood sample, labeling the patient’s red blood cells with a radiotracer (commonly technetium-99m), reinjecting the tagged cells and a known quantity of radiopharmaceutical, then obtaining timed blood samples and counting radioactivity to calculate red blood cell and plasma volumes. The workflow includes pre-procedure consent and allergy review, venous access placement, baseline vital signs, specimen labeling, radiopharmacy preparation of tracer, in-procedure blood draws at specified intervals, laboratory/radiation counts, calculation of total blood, red cell and plasma volumes, documentation of results and interpretation by a nuclear medicine physician, and communication of results to the referring hematologist or cardiologist. Typical site of service is an outpatient nuclear medicine or hospital-based imaging department with capability for radiopharmaceutical handling and inpatient bed availability when clinically indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the physician interpretation/reporting portion separate from technical services. |